Koru Medical Systems, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026, with the SEC on November 10, 2026, reporting a return to quarterly net income alongside continued nine-month revenue growth.

Key Highlights

  • Quarterly net revenues of $11,566,555 for the three months ended September 30, 2026, compared with $10,402,163 for the same period in 2025, according to the filing.
  • Quarterly net income of $218,103 for Q3 2026, versus a net loss of $777,966 in Q3 2025, as reported in the statements of operations.
  • Nine-month net revenues of $35,376,599 for the nine months ended September 30, 2026, compared with $30,232,038 for the same period in 2025.
  • Nine-month net loss of $336,526 for the period ended September 30, 2026, compared with a net loss of $2,151,070 for the nine months ended September 30, 2025.
  • Cash and cash equivalents of $7,364,200 as of September 30, 2026, down from $8,872,212 at December 31, 2025, the filing disclosed.
  • 43,375,176 shares of common stock outstanding as of November 10, 2026, excluding 4,018,526 shares of treasury stock, per the cover page.
  • Total stockholders' equity of $19,395,089 as of September 30, 2026, compared with $17,047,922 at December 31, 2025.

Koru Medical Q3 2026 Financial Results: Revenue Growth and Return to Quarterly Profitability

Koru Medical Systems, Inc. (NASDAQ:KRMD), a Delaware-incorporated medical device company headquartered in Mahwah, New Jersey, reported its unaudited financial results for the three and nine months ended September 30, 2026, in a Form 10-Q filed November 10, 2026. According to the filing, net revenues for the third quarter reached $11,566,555, up from $10,402,163 in Q3 2025. Gross profit for the quarter was $7,546,084, compared with $6,264,571 in the year-earlier period. Total operating expenses for Q3 2026 were $7,358,966, resulting in net operating income of $187,118, versus a net operating loss of $867,679 in Q3 2025.

For the nine months ended September 30, 2026, the company disclosed net revenues of $35,376,599, compared with $30,232,038 for the same period in 2025. The nine-month net loss was $336,526, a significant reduction from the $2,151,070 net loss reported for the nine months ended September 30, 2025. The filing noted a loss on disposal of fixed assets of $406,269 during the nine-month period, which weighed on non-operating results. Research and development expenses for the nine-month period were $3,821,004, up from $3,242,505 in the prior-year period.

On the balance sheet, total assets were $28,784,485 as of September 30, 2026, compared with $28,200,179 at December 31, 2025. Total liabilities decreased to $9,389,396 from $11,152,257 over the same period. The filing also disclosed a non-cash financing activity: during the nine months ended September 30, 2026, the company acquired an intangible asset for $961,035, of which $500,000 was settled through the issuance of 125,628 shares of common stock. Net cash used in operating activities was $652,054 for the nine-month period, compared with $632,351 in the prior-year period.

What Was Disclosed

Koru Medical Systems filed its quarterly report covering the period ended September 30, 2026, disclosing Q3 net income of $218,103 on revenues of $11,566,555, a reduced nine-month net loss of $336,526, and total assets of $28,784,485 as of the balance sheet date.